Cargando…
Vaccines for COVID-19: learning from ten phase II trials to inform clinical and public health vaccination programmes
Public health professionals and clinicians, in many countries, are immersed in the ongoing and upcoming vaccination programmes for COVID-19. Published information from vaccine trials is complex. There are important and helpful insights about the nature of the available and forthcoming vaccines, immu...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Royal Society for Public Health. Published by Elsevier Ltd.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7846205/ https://www.ncbi.nlm.nih.gov/pubmed/33743214 http://dx.doi.org/10.1016/j.puhe.2021.01.011 |
_version_ | 1783644692245643264 |
---|---|
author | Bhopal, Sunil S. Olabi, Bayanne Bhopal, Raj |
author_facet | Bhopal, Sunil S. Olabi, Bayanne Bhopal, Raj |
author_sort | Bhopal, Sunil S. |
collection | PubMed |
description | Public health professionals and clinicians, in many countries, are immersed in the ongoing and upcoming vaccination programmes for COVID-19. Published information from vaccine trials is complex. There are important and helpful insights about the nature of the available and forthcoming vaccines, immune responses and side-effects from phase II trials. We have systematically summarised information from 10 such trials on the nature of the vaccines, exclusions from the trials, immunological effects and side-effects. Some important information within these trial reports is not available in the phase III trial articles, so a complete picture requires examination of phase II and phase III trials for each vaccine. We recommend our systematic approach for the examination of other upcoming COVID-19 vaccine phase II and III trials. |
format | Online Article Text |
id | pubmed-7846205 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | The Royal Society for Public Health. Published by Elsevier Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-78462052021-02-01 Vaccines for COVID-19: learning from ten phase II trials to inform clinical and public health vaccination programmes Bhopal, Sunil S. Olabi, Bayanne Bhopal, Raj Public Health Short Communication Public health professionals and clinicians, in many countries, are immersed in the ongoing and upcoming vaccination programmes for COVID-19. Published information from vaccine trials is complex. There are important and helpful insights about the nature of the available and forthcoming vaccines, immune responses and side-effects from phase II trials. We have systematically summarised information from 10 such trials on the nature of the vaccines, exclusions from the trials, immunological effects and side-effects. Some important information within these trial reports is not available in the phase III trial articles, so a complete picture requires examination of phase II and phase III trials for each vaccine. We recommend our systematic approach for the examination of other upcoming COVID-19 vaccine phase II and III trials. The Royal Society for Public Health. Published by Elsevier Ltd. 2021-04 2021-01-29 /pmc/articles/PMC7846205/ /pubmed/33743214 http://dx.doi.org/10.1016/j.puhe.2021.01.011 Text en © 2021 The Royal Society for Public Health. Published by Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Short Communication Bhopal, Sunil S. Olabi, Bayanne Bhopal, Raj Vaccines for COVID-19: learning from ten phase II trials to inform clinical and public health vaccination programmes |
title | Vaccines for COVID-19: learning from ten phase II trials to inform clinical and public health vaccination programmes |
title_full | Vaccines for COVID-19: learning from ten phase II trials to inform clinical and public health vaccination programmes |
title_fullStr | Vaccines for COVID-19: learning from ten phase II trials to inform clinical and public health vaccination programmes |
title_full_unstemmed | Vaccines for COVID-19: learning from ten phase II trials to inform clinical and public health vaccination programmes |
title_short | Vaccines for COVID-19: learning from ten phase II trials to inform clinical and public health vaccination programmes |
title_sort | vaccines for covid-19: learning from ten phase ii trials to inform clinical and public health vaccination programmes |
topic | Short Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7846205/ https://www.ncbi.nlm.nih.gov/pubmed/33743214 http://dx.doi.org/10.1016/j.puhe.2021.01.011 |
work_keys_str_mv | AT bhopalsunils vaccinesforcovid19learningfromtenphaseiitrialstoinformclinicalandpublichealthvaccinationprogrammes AT olabibayanne vaccinesforcovid19learningfromtenphaseiitrialstoinformclinicalandpublichealthvaccinationprogrammes AT bhopalraj vaccinesforcovid19learningfromtenphaseiitrialstoinformclinicalandpublichealthvaccinationprogrammes |